Category - Markets

Leerink Partners launched coverage of Assembly Biosciences (NASDAQ:ASMB) with an “outperform” rating and $45 price target. The stock closed at $24.67 on Nov. 16. “Our valuation and rating are based on our probability...

A.G.P./ Alliance Global Partners raised its price target for Titan Pharmaceuticals (NASDAQ:TTNP) to 65 cents from 45 cents after the company’s third quarter results exceeded forecasts. The stock closed at 40 cents on...

Leerink Partners initiated coverage of AC Immune (NASDAQ:ACIU) with an “outperform” rating and price target of $18. The stock closed at $9.65 on Nov. 15. AC Immune develops medicines and diagnostic tools for...

Leerink Partners launched coverage of Adamas Pharmaceuticals (NASDAQ:ADMS) with an “outperform” rating and $20 price target. The stock closed at $10.84 on Nov. 15. Adamas applies its drug delivery technology to improve...

Leerink Partners initiated coverage of Intra-Cellular Therapies (NASDAQ:ITCI) with an “outperform” rating and $27 price target. The stock closed at $15.86 on Nov. 14. Intra-Cellular is focused on development of...

Leerink Partners upgraded Mersana Therapeutics (NASDAQ:MRSN) to “outperform” from “market perform” but maintained its price target of $14, citing the stock’s valuation. It closed at $6.04 on Nov. 13. “We are upgrading...

Leerink Partners launched coverage of Biohaven Pharmaceutical Holding (NYSE:BHVN) with an “outperform” rating and $50 price target. The stock closed at $36.90 on Nov. 13. Biohaven is focused on a range of neurological...

Maxim Group launched coverage of Moleculin Biotech (NASDAQ:MBRX) with a “buy” rating and $3 price target. The stock closed at $1.35 on Nov. 13. Moleculin has three differentiated oncology programs: a STAT3 inhibitor for...

SVB Financial Group (NASDAQ:SIVB), the parent company of Silicon Valley Bank, agreed to acquire Leerink Holdings for $280 million. Leerink is a Boston-based parent company of Leerink Partners, a leading investment bank...

William Blair initiated coverage of LogicBio Therapeutics (NASDAQ:LOGC) with an “outperform” rating and $26 fair value estimate. The stock closed at $15.11 on Nov. 12. LogicBio’s GeneRide platform is a promoter-less...